Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LAP3 | P28838 | 4/20 | 0.62 |
| ▸ | LTA4H | P09960 | 2/20 | 0.62 |
| ▸ | MMP8 | P22894 | 1/20 | 0.54 |
| ▸ | ANPEP | P15144 | 3/20 | 0.52 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.52 |
| ▸ | DNPEP | Q9ULA0 | 1/20 | 0.52 |
| ▸ | METAP2 | P50579 | 1/20 | 0.50 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.49 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.48 |
| ▸ | ALPI | P09923 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.47 |
| ▸ | XIAP | P98170 | 1/20 | 0.47 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.47 |
| ▸ | HPRT1 | P00492 | 1/20 | 0.46 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | PPARG | P37231 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL289232 | 1.00 | LAP3 (0.62) | LAP3LTA4HMMP8ANPEPRNPEP | |
| SCHEMBL5699595 | 1.00 | LAP3 (0.62) | LAP3LTA4HMMP8ANPEPRNPEP | |
| Hydrochloric Acid SCHEMBL15310163 | 0.98 | LAP3 (0.60) | LAP3LTA4HMMP8ANPEPRNPEP | |
| Hydrochloric Acid SCHEMBL289130 | 0.98 | LAP3 (0.60) | LAP3LTA4HMMP8ANPEPRNPEP | |
| SCHEMBL7417389 | 0.86 | LTA4H (0.53) | LAP3LTA4HSLC7A5 | |
| SCHEMBL2106650 | 0.85 | LTA4H (0.77) | LAP3LTA4HANPEPRNPEPDNPEP | |
| SCHEMBL6339522 | 0.85 | LTA4H (0.77) | LAP3LTA4HANPEPRNPEPDNPEP | |
| SCHEMBL3445511 | 0.85 | LAP3 (0.81) | LAP3LTA4HANPEPRNPEPDNPEP | |
| SCHEMBL7964846 | 0.85 | LTA4H (0.77) | LAP3LTA4HANPEPRNPEPDNPEP | |
| SCHEMBL8174333 | 0.85 | LTA4H (0.77) | LAP3LTA4HANPEPRNPEPDNPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2714660-B1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2018-09-26 | — | — | EP | disclosed |
| US-20180194757-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-07-12 | — | — | US | disclosed |
| US-20180194757-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-07-12 | — | — | US | disclosed |
| US-20180194757-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-07-12 | — | — | US | disclosed |
| US-20180105503-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-04-19 | — | — | US | disclosed |
| US-20180105503-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-04-19 | — | — | US | disclosed |
| US-20180105503-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-04-19 | — | — | US | disclosed |
| US-9828367-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-11-28 | — | — | US | disclosed |
| US-9828367-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-11-28 | — | — | US | disclosed |
| US-9828367-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-11-28 | — | — | US | disclosed |
| US-20120308588-A1 | NEPRILYSIN INHIBITORS | THERAVANCE, INC. (US) | 2012-12-06 | — | — | US | disclosed |
| US-20120308587-A1 | NEPRILYSIN INHIBITORS | THERAVANCE, INC. (US) | 2012-12-06 | — | — | US | disclosed |
| US-20120308587-A1 | NEPRILYSIN INHIBITORS | THERAVANCE, INC. (US) | 2012-12-06 | — | — | US | disclosed |
| US-20120308587-A1 | NEPRILYSIN INHIBITORS | THERAVANCE, INC. (US) | 2012-12-06 | — | — | US | disclosed |
| US-20120309724-A1 | NEPRILYSIN INHIBITORS | THERAVANCE, INC. (US) | 2012-12-06 | — | — | US | disclosed |
| US-20120309724-A1 | NEPRILYSIN INHIBITORS | THERAVANCE, INC. (US) | 2012-12-06 | — | — | US | disclosed |
| US-20120309724-A1 | NEPRILYSIN INHIBITORS | THERAVANCE, INC. (US) | 2012-12-06 | — | — | US | disclosed |
| WO-2012166389-A1 | NEPRILYSIN INHIBITORS | THERAVANCE, INC. (US) | 2012-12-06 | — | — | WO | disclosed |
| WO-2012166387-A1 | NEPRILYSIN INHIBITORS | THERAVANCE, INC. (US) | 2012-12-06 | — | — | WO | disclosed |
| US-20110021527-A1 | DUAL-ACTING OXAZOLE ANTIHYPERTENSIVE AGENTS | THERAVANCE BIOPHARMA R&D IP, LLC | 2011-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120309724-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | LAP3 70/4885LTA4H 1037/4885MMP8 830/4885 |
| US-20180194757-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | LAP3 40/4885LTA4H 810/4885MMP8 706/4885 |
| US-20120308588-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | LAP3 49/4885LTA4H 869/4885MMP8 833/4885 |
| US-20120308587-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | LAP3 40/4885LTA4H 810/4885MMP8 706/4885 |
| US-20110021527-A1 | DUAL-ACTING OXAZOLE ANTIHYPERTENSIVE AGENTS | AGTR1, AGTR2, REN | LAP3 82/4885LTA4H 1077/4885MMP8 1644/4885 |
| US-20180105503-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | LAP3 70/4885LTA4H 1037/4885MMP8 830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.